MX2021015170A - Formulaciones de medios de micoplasma. - Google Patents

Formulaciones de medios de micoplasma.

Info

Publication number
MX2021015170A
MX2021015170A MX2021015170A MX2021015170A MX2021015170A MX 2021015170 A MX2021015170 A MX 2021015170A MX 2021015170 A MX2021015170 A MX 2021015170A MX 2021015170 A MX2021015170 A MX 2021015170A MX 2021015170 A MX2021015170 A MX 2021015170A
Authority
MX
Mexico
Prior art keywords
mycoplasma
media formulations
vaccines
swine
media
Prior art date
Application number
MX2021015170A
Other languages
English (en)
Inventor
Arvind Kumar
Dharanesh Mahimapura Gangaiah
Original Assignee
Elanco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Us Inc filed Critical Elanco Us Inc
Publication of MX2021015170A publication Critical patent/MX2021015170A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formulaciones de medios libres de suero de cerdo e ingredientes de origen animal (principalmente cerebro bovino y médula espinal) para el crecimiento de micoplasma. Las formulaciones de los medios están diseñadas racionalmente para preservar la antigenicidad de micoplasma. Los micoplasmas cultivados en estas formulaciones de medios son útiles en vacunas, particularmente vacunas porcinas multivalentes.
MX2021015170A 2019-06-10 2020-06-05 Formulaciones de medios de micoplasma. MX2021015170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962859294P 2019-06-10 2019-06-10
PCT/US2020/036297 WO2020251847A1 (en) 2019-06-10 2020-06-05 Mycoplasma media formulations

Publications (1)

Publication Number Publication Date
MX2021015170A true MX2021015170A (es) 2022-03-22

Family

ID=71895191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015170A MX2021015170A (es) 2019-06-10 2020-06-05 Formulaciones de medios de micoplasma.

Country Status (12)

Country Link
US (1) US20220235313A1 (es)
EP (1) EP3980523A1 (es)
JP (1) JP2022536410A (es)
KR (1) KR20220018508A (es)
CN (1) CN114375326A (es)
AU (1) AU2020290984A1 (es)
BR (1) BR112021025021A2 (es)
CA (1) CA3141075A1 (es)
CL (1) CL2021003251A1 (es)
MX (1) MX2021015170A (es)
TW (1) TW202113064A (es)
WO (1) WO2020251847A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
CN104968365B (zh) 2012-12-28 2018-04-03 勃林格殷格翰动物保健有限公司 支原体疫苗的制备方法
CN107674860A (zh) * 2017-07-14 2018-02-09 上海源培生物科技股份有限公司 Nk92细胞无血清培养基

Also Published As

Publication number Publication date
KR20220018508A (ko) 2022-02-15
CA3141075A1 (en) 2020-12-17
BR112021025021A2 (pt) 2022-05-03
AU2020290984A1 (en) 2022-01-20
JP2022536410A (ja) 2022-08-16
US20220235313A1 (en) 2022-07-28
TW202113064A (zh) 2021-04-01
WO2020251847A1 (en) 2020-12-17
CL2021003251A1 (es) 2022-10-07
EP3980523A1 (en) 2022-04-13
CN114375326A (zh) 2022-04-19

Similar Documents

Publication Publication Date Title
CY1121528T1 (el) Ανασυνδυασμενοι φορεις ερπητοϊου gallid 3 (mdv οροτυπου 2) που εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων
AU2019293244A8 (en) Personalized cancer vaccine epitope selection
IN2014DN08830A (es)
MX2021012972A (es) Proteinas de leche recombinantes y composiciones que comprenden las mismas.
IL189313A (en) Virus-like particles as virus-paramixo vaccines, a method for their preparation and use
MX2022015040A (es) Proteina espicular (s) del coronavirus geneticamente manipulada y metodos de uso de la misma.
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
CL2008001383A1 (es) Composición lactea o de sustituto lacteo aireada y liofilizada que comprende un ingrediente lacteo o substituto lacteo, un emulsificante, un mejorador de la viscosidad; y metodo para preparar dicha composicion.
PH12020551637A1 (en) Additives for protein formulations to improve thermal stability
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
WO2009034315A3 (en) Vaccine
PT1951300E (pt) Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
PH12016500894A1 (en) Pediatric nutritional composition with milk peptides for healthy growth and development
WO2018097603A3 (ko) 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
EP3983085A4 (en) NEW ADJUVANT FOR ANIMAL AND HUMAN VACCINES
MX2017000014A (es) Metodo para producir acido graso de cadena media con el uso de beta-cetoacil-proteina portadora de acilo (acp) sintasa.
MX343831B (es) Composicion que comprende proteinas termolabiles de la leche y proceso para su preparacion.
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
AR112892A1 (es) Cepa de bacillus amyloliquefaciens y método para preparar productos de soja fermentada usando el mismo
MX2023004078A (es) Proteinas f de hmpv estabilizadas por prefusion.
WO2009077577A3 (en) Vaccine antigens from piscirickettsia salmonis
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
MX2021015170A (es) Formulaciones de medios de micoplasma.